Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.76 - $2.41 $1.78 Million - $2.43 Million
-1,009,541 Reduced 73.64%
361,406 $643,000
Q3 2021

Nov 15, 2021

SELL
$1.89 - $8.53 $4.36 Million - $19.7 Million
-2,307,679 Reduced 62.73%
1,370,947 $6.64 Million
Q2 2021

Aug 16, 2021

BUY
$2.46 - $3.14 $1.11 Million - $1.41 Million
449,200 Added 13.91%
3,678,626 $9.82 Million
Q1 2021

May 17, 2021

BUY
$2.86 - $4.77 $3.68 Million - $6.13 Million
1,285,714 Added 66.15%
3,229,426 $9.95 Million
Q4 2020

Feb 12, 2021

BUY
$3.56 - $4.86 $712,000 - $972,000
200,000 Added 11.47%
1,943,712 $6.92 Million
Q3 2020

Nov 13, 2020

BUY
$2.6 - $5.37 $4,160 - $8,592
1,600 Added 0.09%
1,743,712 $6.99 Million
Q2 2020

Aug 14, 2020

SELL
$2.01 - $4.05 $833,402 - $1.68 Million
-414,628 Reduced 19.22%
1,742,112 $4.74 Million
Q1 2020

May 15, 2020

BUY
$1.74 - $5.98 $920,759 - $3.16 Million
529,172 Added 32.51%
2,156,740 $4.55 Million
Q4 2019

Feb 14, 2020

SELL
$2.56 - $5.44 $3.63 Million - $7.72 Million
-1,419,587 Reduced 46.59%
1,627,568 $8.85 Million
Q3 2019

Nov 14, 2019

BUY
$3.01 - $6.5 $819,939 - $1.77 Million
272,405 Added 9.82%
3,047,155 $9.17 Million
Q2 2019

Aug 14, 2019

BUY
$3.3 - $4.58 $2.2 Million - $3.05 Million
665,408 Added 31.55%
2,774,750 $10.4 Million
Q1 2019

May 15, 2019

BUY
$3.75 - $4.97 $820,631 - $1.09 Million
218,835 Added 11.58%
2,109,342 $8.48 Million
Q2 2018

Aug 14, 2018

SELL
$9.42 - $13.73 $600,496 - $875,246
-63,747 Reduced 3.26%
1,890,507 $20.8 Million
Q1 2018

May 07, 2018

BUY
$7.48 - $11.53 $11.2 Million - $17.2 Million
1,494,858 Added 325.4%
1,954,254 $22.5 Million
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $5.19 Million - $7.92 Million
459,396
459,396 $7.32 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.